As of November 6, 2026, Inmune Bio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 14, 2026 (Form 8-K, September 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Inmune Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Inmune Bio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-14. Every row below is cited to the filing it comes from, and this page adds each new change as Inmune Bio, Inc. files it.
Also on the record for Inmune Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Highbridge Capital Management, LLC | 5.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Kupperman Harris | 3.4% of the class | 5%+ stakes | Source |
| July 2, 2025 | Stake report, Schedule 13G, by CVI Investments, Inc. | 5.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Inmune Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Inmune Bio, Inc. and the records around it.
Inmune Bio, Inc. elsewhere on the record
- 5%+ stake filings Aug 2025
- Who owns it
Companies that share a holder
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Inmune Bio, Inc.
Get an email when Inmune Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Inmune Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Inmune Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inmune Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-14 | Reported | not named in the filing | 8-K, 2026-09-14 |
New leaders reset buying decisions — get the Full Report on Inmune Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Inmune Bio, Inc., with the record behind each one.
Find candidates like senior executive at Inmune Bio, Inc.Every change, in the filing's words
Reported
On September 8, 2026, the Board of Directors (the "Board") of INmune Bio, Inc. (the "Company") approved to increase the number of directors and to set the number of directors serving on the Board at seven, and, pursuant to the Company's by-Laws, appointed R. Duane Clark II and James Sapirstein to serve as directors of the Company until the next annual election and until their successors are duly elected and qualified.
- The Board also appointed Mr. Clark and Mr. Sapirstein to serve as members of the Nominating and Corporate Governance Committee of the Board.
- Mr. Clark, age 63, brings more than 40 years of global pharmaceutical and biotechnology leadership, with particular depth in rare diseases, immunology and specialty-product commercialization.
- He currently serves as General Manager, U.S. Rare Diseases at Sanofi, where he leads a multi-billion-dollar business spanning seven rare-disease brands with full profit-and-loss responsibility.
- His experience includes multiple product launches, market-access strategy, M&A integration, and leadership across sales, marketing, medical and commercial operations.
- Earlier in his career, he led Sanofi's U.K. and Ireland multiple sclerosis business and held commercial and business-development roles at CTI Clinical Trial & Consulting Services, Encysive Pharmaceuticals, Astellas Pharma, Ortho Biotech and Marion Laboratories.
- Mr. Clark received a B.A. in Business and Marketing from University of Kentucky.
- Mr. Sapirstein, age 65, brings more than 40 years of biopharmaceutical leadership spanning business development, licensing, commercialization, capital formation and public-company operating experience.
- He has led six global commercial product launches and participated in more than 20 additional launches.
Tools for this story
Each opens in a new tab, filled in for Inmune Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.